Cost savings with nefazodone in treating depression

Robert E Hales, Donald M. Hilty, Gregory H. Brunson

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Pharmacoeconomic analysis of antidepressant therapy is an important tool for ensuring the most cost-cognizant approach to treat a particular mental disorder. As the number of effective antidepressant compounds continues to grow, the drug selection process must consider not only the cost of the drug itself, but also costs associated with treatment failure and management of untoward and unexpected side effects. In economic studies conducted in North America and England using a decision analysis model and a direct annual cost model, nefazodone has been shown to have an impact on costs associated with depression when compared with imipramine and fluoxetine. Nefazodone also can reduce depression-related anxiety and agitation symptoms early in treatment, and, because it improves subjective and objective sleep measures, use of concomitant anxiolytics or sedative-hypnotics with nefazodone has been shown to be less frequent and less costly than with selective serotonin reuptake inhibitors.

Original languageEnglish (US)
Pages (from-to)48-51
Number of pages4
JournalJournal of Clinical Psychiatry
Volume63
Issue numberSUPPL. 1
StatePublished - 2002

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Fingerprint Dive into the research topics of 'Cost savings with nefazodone in treating depression'. Together they form a unique fingerprint.

Cite this